NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Learn more

Workspace · Cancer algorithms · Thyroid

Thyroid

Thyroid · 45,240 new · 2,320 deaths (ACS 2026) · mortality 0.5 per 100k · 5-yr RS 98.3% (SEER)

Mortality 0.5 per 100k (SEER / ACS common-sites). Never an artboard percent.

1,035,274 people living with thyroid cancer in 2023 (SEER Stat Facts). Lifetime is not restated here — it collides with a locked artboard figure. No encoded screening interval.

1,035,274 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 51 · at death 74 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 7.4 / women 20.0 per 100k · mortality men 0.5 / women 0.5 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 55–64. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases stable (2014–2023). Death rates stable (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic Asian/Pacific Islander women 22.3 per 100k. Highest death rate: Hispanic women 0.7 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
GroupInc. menInc. womenDeaths menDeaths women
Hispanic6.121.20.50.7
Non-Hispanic American Indian/Alaska Native5.617.00.50.6
Non-Hispanic Asian/Pacific Islander7.722.30.50.7
Non-Hispanic Black3.612.10.40.5
Non-Hispanic White8.620.80.50.4

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

USPSTF 2017 D · Asymptomatic adults · Do not screen

Cited only. No screening interval and no unpublished coefficient. USPSTF-thyroid-2017

ACS early-detection pointer

ACS 2024 · Most people considering thyroid-cancer screening · ACS (2024): screening for thyroid cancer is not recommended for most people. Complementary to the cited USPSTF 2017 D statement. Official lifetime-risk figures are not restated. Not a neck-ultrasound screening engine.

Cited ACS statement only. Not a screening engine. ACS-thyroid-detect

Surveillance pointer

ACS-thyroid-follow 2024 · cited only · ACS living-as-a-survivor page names neck exams, TSH, and thyroglobulin testing after thyroid treatment. Those months are not encoded. Official lifetime-risk figures are not restated. Not a thyroglobulin surveillance engine.

Named public source only. Not a personal follow-up calendar. ACS-thyroid-follow

Surveillance pointer

ACS-thyroid-follow 2024 · cited only · ACS living-as-a-survivor page names later cancers after thyroid-cancer treatment, including breast, prostate, kidney, and adrenal, plus ALL, stomach, and salivary gland after radioactive iodine. Named later-cancer sites are not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not a thyroglobulin or neck-ultrasound engine. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-thyroid-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names hypothyroidism after thyroidectomy, radioactive iodine, head-and-neck radiation, or high-dose chemo, and says the doctor may check thyroid levels every so often. Those names are not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not a thyroglobulin or neck-ultrasound engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a yearly thyroid exam after radiation to the head, neck, or throat, plus a treatment summary and survivorship care plan. Those named tests and plans are not encoded. Complementary to the living-as and late-effects pointers. Official lifetime figures are not restated. Not a thyroglobulin or neck-ultrasound engine. No invented printout field.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-thyroid-follow 2024 · empty on purpose · ACS living-as-a-survivor page names long-term treatment effects. Those late effects are not encoded. Official lifetime-risk figures are not restated. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-thyroid-follow

Toxicity pointer

ACS-thyroid-follow 2024 · empty on purpose · ACS living-as-a-survivor page names later cancers after thyroid-cancer treatment. Those second-cancer risks are not encoded. Official lifetime figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-thyroid-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later hypothyroidism after thyroidectomy, radioactive iodine, or head-and-neck radiation. Those late effects are not encoded. Official lifetime figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a yearly thyroid exam after head, neck, or throat radiation. That named test is not encoded. Official lifetime figures are not restated. Complementary to the living-as pointer. No invented printout field. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.

Kidney, thyroid, and leukemia stay unmapped. Cadences are not encoded.

All printouts →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-thyroid · stub · none · v2-stub-thyroid

SEER 5-year relative survival by stage (cited stub)

Localized 99.9% · Regional 98.1% · Distant 48.3% · All 98.3%

Lifetime is not restated here — it collides with a locked artboard figure.

Percent of cases by stage (SEER Stat Facts)

Localized 63% · Regional 31% · Distant 3% · Unknown 3%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Lifetime is not restated here.

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2017 D — do not screen asymptomatic adults

    Cited USPSTF 2017 D and ACS 2024 statements. No neck-ultrasound screening engine. Official lifetime-risk figures are not restated.

    not encoded

  • surveillance

    ACS follow-up cited — thyroglobulin months not encoded

    Cited ACS living-as-a-survivor page only. Official lifetime-risk figures are not restated.

    not encoded

  • toxicity

    ACS late effects cited — thyroid months not encoded

    Empty on purpose. Official lifetime-risk figures are not restated.

    not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2017 D — do not screen asymptomatic adults

    Cited USPSTF 2017 D and ACS 2024 statements. No neck-ultrasound screening engine. Official lifetime-risk figures are not restated.

    not encoded

  • surveillance

    ACS follow-up cited — thyroglobulin months not encoded

    Cited ACS living-as-a-survivor page only. Official lifetime-risk figures are not restated.

    not encoded

  • toxicity

    ACS late effects cited — thyroid months not encoded

    Empty on purpose. Official lifetime-risk figures are not restated.

    not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2017 D — do not screen asymptomatic adults

    Cited USPSTF 2017 D and ACS 2024 statements. No neck-ultrasound screening engine. Official lifetime-risk figures are not restated.

    not encoded

  • surveillance

    ACS follow-up cited — thyroglobulin months not encoded

    Cited ACS living-as-a-survivor page only. Official lifetime-risk figures are not restated.

    not encoded

  • toxicity

    ACS late effects cited — thyroid months not encoded

    Empty on purpose. Official lifetime-risk figures are not restated.

    not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    USPSTF 2017 D — do not screen asymptomatic adults

    Cited USPSTF 2017 D and ACS 2024 statements. No neck-ultrasound screening engine. Official lifetime-risk figures are not restated.

    not encoded

  • surveillance

    ACS follow-up cited — thyroglobulin months not encoded

    Cited ACS living-as-a-survivor page only. Official lifetime-risk figures are not restated.

    not encoded

  • toxicity

    ACS late effects cited — thyroid months not encoded

    Empty on purpose. Official lifetime-risk figures are not restated.

    not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →